The global anti-hypertensive drugs market is anticipated to grow at a CAGR of over 4% during the forecast period. The anti-hypertensive drugs are used to restrict any complications of high blood pressure including myocardial infarction, stroke, and many more. In addition to this, anti-hypertensive drugs have their primary action on systemic vascular resistance and it also reduces systemic vascular resistance with long-term use. Moreover, hypertension is directly associated with increased cardiovascular risk, and reducing blood pressure and the use of the anti-hypertensive drug is recommended which significantly decreases such risks. Hence, factors such as increasing cases of diabetes, hypertension, cardiovascular diseases associated with high blood pressure will directly impact the growth of the global anti-hypertensive market during the forecast period.
To Request a Sample of our Report on Anti-Hypertensive Drugs Market: https://www.omrglobal.com/request-sample/anti-hypertensive-drugs-market
However, the high cost associated with anti-hypertensive drugs will turn out to be a major restraint for the growth of the anti-hypertensive market, as it has to be given to the patient for a longer period. Additionally, the low awareness and less diagnosis rate in the developing countries will also hamper the growth of the anti-hypertensive drugs market during the forecast period. Moreover, the side effects of anti-hypertensive drugs such as calcium channel blockers used during pregnancy include tachycardia, palpitations, peripheral edema, headaches, and facial flushing, which will lower the adoption of these drugs. Hence, the low adoption rate of anti-hypertensive drugs during pregnancy will majorly restrict the growth of the anti-hypertensive drug market during the forecast period.
(Get 15% Discount on Buying this Report)
A full Report of Anti-Hypertensive Drugs Market is Available at: https://www.omrglobal.com/industry-reports/anti-hypertensive-drugs-market
Global Antihypertensive Drugs Market Segmentation
By Drug Class
· Thiazide Diuretics
· Calcium Channel Blockers
· ACE Inhibitors
· Angiotensin II Receptor Antagonists (ARBS)
· Beta Blockers
· Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
